Moleculin plans Annamycin pancreatic cancer trial in 2027
MBRX•Moleculin Biotech said Annamycin combined with PD-1 checkpoint blockade extended survival in pancreatic cancer mice compared with either treatment alone. The company plans an investigator-initiated pancreatic cancer trial in 2027.
1. Preclinical findings
Moleculin Biotech announced preclinical results showing that Annamycin combined with PD-1 checkpoint blockade extended survival in pancreatic cancer mice versus either treatment alone. A second independent experiment confirmed the survival benefit. The findings are to be presented at the Marie Skłodowska-Curie Symposium on Cancer Research and Care in Tampa, Florida.
2. Trial plans
An investigator-initiated pancreatic cancer trial is planned for 2027. The MIRACLE trial in acute myeloid leukemia remains the immediate priority, with a data readout expected in the first quarter of 2027.
